Clinical experience with sonographic contrast agents.
Early generations of sonographic contrast agents are beginning to reach the attention of the clinician. Research and development of ultrasound contrast agents is progressing at a rapid pace with several new agents approaching US Food and Drug Administration approval. Cardiac imaging has been affected by even the limited availability of contrast agents on the market today both with regard to diagnosis of shunts and chamber opacification, and most recently actual enhancement of the myocardium. Later generations of contrast are capable of providing consistent opacification of both peripheral veins and arteries, and should prove useful in a variety clinical applications. Thus far, it appears that longer vessel segments may be seen with contrast rather than without contrast, and that flow may be demonstrated in vessels which were not seen or thought to be occluded with conventional color imaging. Improved detection of arterial and venous collaterals and enhanced identification of run-off vessels is demonstrated with sonographic contrast agents. An improved ability to evaluate renal artery stenosis and subtotal occlusion of the carotid artery are specific advantages of using contrast as well. Several compounds are currently being tested that may allow routine parenchymal opacification. Ultrasound is the most commonly performed diagnostic imaging procedure; therefore, contrast agents have the potential to dramatically alter the practice of clinical medicine. This article reviews the current status of ultrasound contrast agents and speculates regarding the future applications of these agents.
Melany
M L
ML
West Los Angeles VA Medical Center, CA 90073, USA.
Grant
E G
EG
D000418:Albumins; D016477:Artifacts; D003287:Contrast Media; D004452:Echocardiography; D006801:Humans; D007089:Image Enhancement; D012078:Renal Artery Obstruction / Q000000981:diagnostic imaging; D014463:Ultrasonography
D000418:Albumins; C060687:Albunex; D003287:Contrast Media